دورية أكاديمية
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
| العنوان: | Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials. |
|---|---|
| المؤلفون: | Minnema MC; University Medical Center Utrecht, Utrecht, Netherlands., Yin X; Medidata Solutions, New York, NY, USA., Davi R; Medidata Solutions, New York, NY, USA., Keeping S; PRECISIONheor, Vancouver, Canada., Park JE; PRECISIONheor, Vancouver, Canada., Itani T; Kite, a Gilead Company, Santa Monica, CA, USA., Hadjivassileva T; Kite, a Gilead Company, Santa Monica, CA, USA., Castaigne JG; Kite, a Gilead Company, Santa Monica, CA, USA., Damico Khalid R; Kite, a Gilead Company, Santa Monica, CA, USA., Zhou L; Kite, a Gilead Company, Santa Monica, CA, USA., Wu JJ; Kite, a Gilead Company, Santa Monica, CA, USA., Shah BD; Moffitt Cancer Center, Tampa, FL, USA. |
| المصدر: | Leukemia & lymphoma [Leuk Lymphoma] 2024 May 24, pp. 1-10. Date of Electronic Publication: 2024 May 24. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [Philadelphia, PA] : Taylor & Francis Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989- |
| مستخلص: | Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the USA and European Union (EU) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL; aged ≥26 years in EU). Here, outcomes for patients with R/R B-ALL aged ≥26 years in ZUMA-3 treated with brexu-cel were compared with historical standard-of-care (SOC) therapy. After median follow-up of 26.8 months, the overall complete remission (CR) rate among patients treated with brexu-cel in Phase 2 ( N = 43) was 72% and median overall survival (OS) was 25.4 months (95% CI, 15.9-NE). Median OS was improved in Phase 2 patients versus matched historical SOC-treated patients. Compared with aggregate historical trial data, Phase 1 and 2 patients had improved OS versus blinatumomab, inotuzumab, and chemotherapy in a matching-adjusted indirect comparison (MAIC) study. These data demonstrate clinical benefit of brexu-cel relative to SOC in patients ≥26 years with R/R B-ALL. |
| فهرسة مساهمة: | Keywords: B-cell acute lymphoblastic leukemia; CAR T-cell therapy; CD-19; SCHOLAR-3; ZUMA-3; brexucabtagene autoleucel |
| تواريخ الأحداث: | Date Created: 20240524 Latest Revision: 20240524 |
| رمز التحديث: | 20240524 |
| DOI: | 10.1080/10428194.2024.2353877 |
| PMID: | 38785408 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2024.2353877 |